Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 People who’ve had radiotherapy shape our new policy calls May 4, 2023 Delivering the future of paediatric brain tumour therapy October 7, 2021 Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... May 11, 2021 Load more HOT NEWS Oncolytic Virus Enables the Immune System to Attack Tumors The Gift of Time Experimental mRNA Vaccine Hints at Potential Against Glioblastoma News digest – skin cancer deaths, Public Health England plans and...
